JPH10504442A - α（１，３）ガラクトシルトランスフェラーゼ陰性ブタ - Google Patents
α（１，３）ガラクトシルトランスフェラーゼ陰性ブタInfo
- Publication number
- JPH10504442A JPH10504442A JP7526984A JP52698495A JPH10504442A JP H10504442 A JPH10504442 A JP H10504442A JP 7526984 A JP7526984 A JP 7526984A JP 52698495 A JP52698495 A JP 52698495A JP H10504442 A JPH10504442 A JP H10504442A
- Authority
- JP
- Japan
- Prior art keywords
- pig
- galactosyltransferase
- gene
- sequence
- transgenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108060003306 Galactosyltransferase Proteins 0.000 title claims abstract description 75
- 102000030902 Galactosyltransferase Human genes 0.000 title claims abstract description 62
- 230000009261 transgenic effect Effects 0.000 claims abstract description 43
- 241000282887 Suidae Species 0.000 claims abstract description 24
- 230000014509 gene expression Effects 0.000 claims abstract description 22
- 210000000056 organ Anatomy 0.000 claims abstract description 14
- 102000004190 Enzymes Human genes 0.000 claims abstract description 12
- 108090000790 Enzymes Proteins 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 76
- 108020004414 DNA Proteins 0.000 claims description 53
- 239000013598 vector Substances 0.000 claims description 35
- 108091092562 ribozyme Proteins 0.000 claims description 28
- 108090000994 Catalytic RNA Proteins 0.000 claims description 27
- 102000053642 Catalytic RNA Human genes 0.000 claims description 27
- 238000012546 transfer Methods 0.000 claims description 25
- 230000008685 targeting Effects 0.000 claims description 21
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims description 17
- 108020004999 messenger RNA Proteins 0.000 claims description 16
- 108090000992 Transferases Proteins 0.000 claims description 15
- 239000003550 marker Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 238000002744 homologous recombination Methods 0.000 claims description 14
- 230000006801 homologous recombination Effects 0.000 claims description 14
- 230000000692 anti-sense effect Effects 0.000 claims description 12
- 102000004357 Transferases Human genes 0.000 claims description 11
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 11
- 150000007523 nucleic acids Chemical group 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 230000002759 chromosomal effect Effects 0.000 claims description 5
- 210000000287 oocyte Anatomy 0.000 claims description 3
- 238000013519 translation Methods 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 239000004020 conductor Substances 0.000 claims 2
- 102000053602 DNA Human genes 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 230000002779 inactivation Effects 0.000 abstract description 4
- 125000000837 carbohydrate group Chemical group 0.000 abstract description 3
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 111
- 241001465754 Metazoa Species 0.000 description 59
- 210000001161 mammalian embryo Anatomy 0.000 description 25
- 241000282898 Sus scrofa Species 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 24
- 108700028369 Alleles Proteins 0.000 description 22
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 230000000295 complement effect Effects 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 238000002054 transplantation Methods 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 241000283690 Bos taurus Species 0.000 description 13
- 238000010363 gene targeting Methods 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 210000002257 embryonic structure Anatomy 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 230000010354 integration Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 210000002459 blastocyst Anatomy 0.000 description 9
- 244000309715 mini pig Species 0.000 description 9
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 238000000520 microinjection Methods 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 210000003101 oviduct Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 241001045988 Neogene Species 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000004602 germ cell Anatomy 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 101150091879 neo gene Proteins 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 4
- 229960002963 ganciclovir Drugs 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000006771 Gonadotropins Human genes 0.000 description 3
- 108010086677 Gonadotropins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010025815 Kanamycin Kinase Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000251131 Sphyrna Species 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 102000054766 genetic haplotypes Human genes 0.000 description 3
- 239000002622 gonadotropin Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000000472 morula Anatomy 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical class OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 206010042573 Superovulation Diseases 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000004246 corpus luteum Anatomy 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000009027 insemination Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 210000005000 reproductive tract Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000031872 Body Remains Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100022404 E3 ubiquitin-protein ligase Midline-1 Human genes 0.000 description 1
- 101710102210 E3 ubiquitin-protein ligase Midline-1 Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000063963 Jodia Species 0.000 description 1
- 102100034866 Kallikrein-6 Human genes 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004952 blastocoel Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- -1 lactose amino polysaccharide Chemical class 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 125000005642 phosphothioate group Chemical group 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108091008077 processed pseudogenes Proteins 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01228—Lactosylceramide 4-alpha-galactosyltransferase (2.4.1.228)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
- A01K2267/025—Animal producing cells or organs for transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/02—Cells from transgenic animals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/52—Vector systems having a special element relevant for transcription encoding ribozyme for self-inactivation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22893394A | 1994-04-13 | 1994-04-13 | |
| US08/228,933 | 1994-04-13 | ||
| PCT/US1995/003940 WO1995028412A1 (en) | 1994-04-13 | 1995-03-31 | α(1,3) GALACTOSYLTRANSFERASE NEGATIVE SWINE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007026119A Division JP2007175057A (ja) | 1994-04-13 | 2007-01-10 | α（１，３）ガラクトシルトランスフェラーゼ陰性ブタ |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH10504442A true JPH10504442A (ja) | 1998-05-06 |
Family
ID=22859145
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7526984A Pending JPH10504442A (ja) | 1994-04-13 | 1995-03-31 | α（１，３）ガラクトシルトランスフェラーゼ陰性ブタ |
| JP2007026119A Pending JP2007175057A (ja) | 1994-04-13 | 2007-01-10 | α（１，３）ガラクトシルトランスフェラーゼ陰性ブタ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007026119A Pending JP2007175057A (ja) | 1994-04-13 | 2007-01-10 | α（１，３）ガラクトシルトランスフェラーゼ陰性ブタ |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6153428A (OSRAM) |
| EP (1) | EP0755402B1 (OSRAM) |
| JP (2) | JPH10504442A (OSRAM) |
| AT (1) | ATE395418T1 (OSRAM) |
| AU (1) | AU2233295A (OSRAM) |
| CA (1) | CA2187802A1 (OSRAM) |
| DE (1) | DE69535752D1 (OSRAM) |
| IL (1) | IL113238A0 (OSRAM) |
| WO (1) | WO1995028412A1 (OSRAM) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6331658B1 (en) * | 1993-04-20 | 2001-12-18 | Integris Baptist Medical Center, Inc. | Genetically engineered mammals for use as organ donors |
| US5849991A (en) * | 1994-01-27 | 1998-12-15 | Bresatch Limited | Mice homozygous for an inactivated α 1,3-galactosyl transferase gene |
| JPH10507906A (ja) * | 1994-08-19 | 1998-08-04 | ザ ジェネラル ホスピタル コーポレイション | 遺伝子工学処理したブタ細胞 |
| US5984858A (en) * | 1995-06-07 | 1999-11-16 | Crosscart, Inc. | Meniscal xenografts |
| US5913900A (en) * | 1995-06-07 | 1999-06-22 | Corsscart, Inc. | Substantially native meniscal cartilage heterografts |
| US5865849A (en) * | 1995-06-07 | 1999-02-02 | Crosscart, Inc. | Meniscal heterografts |
| US6046379A (en) * | 1995-06-07 | 2000-04-04 | Stone; Kevin R. | Meniscal xenografts |
| US6231608B1 (en) | 1995-06-07 | 2001-05-15 | Crosscart, Inc. | Aldehyde and glycosidase-treated soft and bone tissue xenografts |
| US5902338A (en) * | 1995-09-15 | 1999-05-11 | Crosscart, Inc. | Anterior cruciate ligament heterograft |
| US6049025A (en) * | 1995-09-15 | 2000-04-11 | Stone; Kevin R. | Articular cartilage xenografts |
| US5944755A (en) * | 1995-09-15 | 1999-08-31 | Crosscart, Inc. | Articular cartilage xenografts |
| US6210440B1 (en) | 1995-09-15 | 2001-04-03 | Kevin R. Stone | Anterior cruciate ligament xenografts |
| US5782915A (en) * | 1995-09-15 | 1998-07-21 | Stone; Kevin R. | Articular cartilage heterografts |
| US6110206A (en) | 1995-09-15 | 2000-08-29 | Crosscart, Inc. | Anterior cruciate ligament xenografts |
| US6166288A (en) * | 1995-09-27 | 2000-12-26 | Nextran Inc. | Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor |
| JP2000514641A (ja) * | 1995-11-03 | 2000-11-07 | ザ マウント シナイ メディカル センター | 異種移植拒絶を低減するための方法および組成物 |
| US6235969B1 (en) * | 1997-01-10 | 2001-05-22 | University Of Massachusetts | Cloning pigs using donor nuclei from non-quiescent differentiated cells |
| US6011197A (en) | 1997-03-06 | 2000-01-04 | Infigen, Inc. | Method of cloning bovines using reprogrammed non-embryonic bovine cells |
| CA2349562A1 (en) | 1998-03-06 | 1999-09-10 | Crosscart, Inc. | Soft tissue xenografts |
| US6972041B1 (en) | 1998-03-16 | 2005-12-06 | Crosscart, Inc. | Bone xenografts |
| US6383732B1 (en) | 1999-02-11 | 2002-05-07 | Crosscart, Inc. | Method of preparing xenograft heart valves |
| US6509187B2 (en) * | 1998-05-25 | 2003-01-21 | Agrobiogen Gmbh | Method and device for collection and preparation of tissue samples for molecular genetic diagnostics |
| JP2990268B1 (ja) * | 1998-08-31 | 1999-12-13 | 工業技術院長 | 機能性核酸転写用発現系 |
| ES2196864T3 (es) * | 1998-09-25 | 2003-12-16 | Deutsches Krebsforsch | Secuencia antisentido para la inhibicion de la expresion de la molecula de adhesion icam-1. |
| WO2000022098A1 (en) | 1998-10-12 | 2000-04-20 | Geron Bio-Med Limited | Porcine oocytes with improved developmental competence |
| WO2000024912A1 (en) * | 1998-10-23 | 2000-05-04 | The Children's Medical Center Corporation | Use of a self-cleaving rna motif to modulate gene expression |
| US6258998B1 (en) | 1998-11-24 | 2001-07-10 | Infigen, Inc. | Method of cloning porcine animals |
| US6700037B2 (en) | 1998-11-24 | 2004-03-02 | Infigen, Inc. | Method of cloning porcine animals |
| US6267786B1 (en) | 1999-02-11 | 2001-07-31 | Crosscart, Inc. | Proteoglycan-reduced soft tissue xenografts |
| US20020012660A1 (en) * | 1999-03-04 | 2002-01-31 | Alan Colman | Method of preparing a somatic cells for nuclear transfer |
| WO2001023541A2 (en) * | 1999-09-30 | 2001-04-05 | Alexion Pharmaceuticals, Inc. | Compositions and methods for altering gene expression |
| WO2001030992A2 (en) * | 1999-10-22 | 2001-05-03 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | α1-3 GALACTOSYLTRANSFERASE GENE AND PROMOTER |
| WO2001035735A1 (en) * | 1999-11-19 | 2001-05-25 | Hematech, Llc | Production of ungulates, preferably bovines that produce human immunoglobulins |
| US7414170B2 (en) | 1999-11-19 | 2008-08-19 | Kirin Beer Kabushiki Kaisha | Transgenic bovines capable of human antibody production |
| US7820878B2 (en) | 1999-11-19 | 2010-10-26 | Kyowa Hakko Kirin Co., Ltd. | Production of ungulates, preferably bovines that produce human immunoglobulins |
| US7074983B2 (en) | 1999-11-19 | 2006-07-11 | Kirin Beer Kabushiki Kaisha | Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin |
| US20020142397A1 (en) * | 2000-12-22 | 2002-10-03 | Philippe Collas | Methods for altering cell fate |
| US7491534B2 (en) | 2000-12-22 | 2009-02-17 | Kirin Holdings Kabushiki Kaisha | Methods for altering cell fate to generate T-cells specific for an antigen of interest |
| AU2002232858B2 (en) | 2000-12-22 | 2007-01-11 | Sab, Llc | Methods for cloning mammals using reprogrammed donor chromatin or donor cells |
| US7126039B2 (en) | 2001-03-21 | 2006-10-24 | Geron Corporation | Animal tissue with carbohydrate antigens compatible for human transplantation |
| AU2002242538B2 (en) * | 2001-03-21 | 2007-06-28 | Geron Corporation | Animal tissue with carbohydrate antigens compatible for human transplantation |
| US20030153044A1 (en) * | 2001-05-14 | 2003-08-14 | Monika Liljedahl | Tissues or organs for use in xenotransplantation |
| US20030092174A1 (en) * | 2001-05-14 | 2003-05-15 | Monika Liljedahl | Tissues or organs for use in xenotransplantation |
| US6702744B2 (en) | 2001-06-20 | 2004-03-09 | Advanced Cardiovascular Systems, Inc. | Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery |
| WO2003005810A2 (en) * | 2001-07-09 | 2003-01-23 | Alexion Pharmaceuticals Inc. | Cloned non-human mammals from contact inhibited donor cells |
| US8608661B1 (en) | 2001-11-30 | 2013-12-17 | Advanced Cardiovascular Systems, Inc. | Method for intravascular delivery of a treatment agent beyond a blood vessel wall |
| WO2003055302A1 (en) * | 2001-12-21 | 2003-07-10 | The Curators Of The University Of Missouri | Knockout swine and methods for making the same |
| JP2003225089A (ja) * | 2002-02-04 | 2003-08-12 | National Institute Of Agrobiological Sciences | ブタｒａｇ−１遺伝子およびその利用 |
| US7361368B2 (en) | 2002-06-28 | 2008-04-22 | Advanced Cardiovascular Systems, Inc. | Device and method for combining a treatment agent and a gel |
| WO2004016742A2 (en) * | 2002-08-14 | 2004-02-26 | Immerge Biotherapeutics, Inc. | α(1,3)-GALACTOSYLTRANSFERASE NULL CELLS, METHODS OF SELECTING AND α(1,3)-GALACTOSYLTRANSFERASE NULL SWINE PRODUCED THEREFROM |
| EP3170890A1 (en) | 2002-08-21 | 2017-05-24 | Revivicor, Inc. | Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase |
| KR20050093761A (ko) | 2002-11-08 | 2005-09-23 | 헤마테크, 엘엘씨 | 프리온 단백질 활성이 감소된 트랜스제닉 유제동물 및 그의용도 |
| US8821473B2 (en) | 2003-04-15 | 2014-09-02 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
| US8038991B1 (en) | 2003-04-15 | 2011-10-18 | Abbott Cardiovascular Systems Inc. | High-viscosity hyaluronic acid compositions to treat myocardial conditions |
| US8383158B2 (en) | 2003-04-15 | 2013-02-26 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
| AU2004259019B2 (en) | 2003-07-21 | 2010-09-23 | Lifecell Corporation | Acellular tissue matrices made from galactose alpha-1,3-galactose-deficient tissue |
| EP1685148A2 (en) | 2003-11-05 | 2006-08-02 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION |
| KR20070002057A (ko) | 2004-03-17 | 2007-01-04 | 레비비코르 인코포레이션 | 기능성 알파 1,3 갈락토실트랜스펙션스페라제의 어떠한발현도 결여된 동물로부터 유래된 조직 산물 |
| CA2563064A1 (en) * | 2004-04-22 | 2005-11-10 | Kirin Beer Kabushiki Kaisha | Transgenic animals and uses thereof |
| WO2005117576A2 (en) * | 2004-05-28 | 2005-12-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Modification of sugar metabolic process in transgenic cells, tissues and animals |
| US20060148080A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Methods for supporting and producing human cells and tissues in non-human mammal hosts |
| US20060147429A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Facilitated cellular reconstitution of organs and tissues |
| US20080125745A1 (en) | 2005-04-19 | 2008-05-29 | Shubhayu Basu | Methods and compositions for treating post-cardial infarction damage |
| US8828433B2 (en) | 2005-04-19 | 2014-09-09 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
| US8303972B2 (en) | 2005-04-19 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
| US9539410B2 (en) | 2005-04-19 | 2017-01-10 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating post-cardial infarction damage |
| US8187621B2 (en) | 2005-04-19 | 2012-05-29 | Advanced Cardiovascular Systems, Inc. | Methods and compositions for treating post-myocardial infarction damage |
| US7732190B2 (en) | 2006-07-31 | 2010-06-08 | Advanced Cardiovascular Systems, Inc. | Modified two-component gelation systems, methods of use and methods of manufacture |
| US9242005B1 (en) | 2006-08-21 | 2016-01-26 | Abbott Cardiovascular Systems Inc. | Pro-healing agent formulation compositions, methods and treatments |
| US9005672B2 (en) | 2006-11-17 | 2015-04-14 | Abbott Cardiovascular Systems Inc. | Methods of modifying myocardial infarction expansion |
| US8741326B2 (en) | 2006-11-17 | 2014-06-03 | Abbott Cardiovascular Systems Inc. | Modified two-component gelation systems, methods of use and methods of manufacture |
| US8192760B2 (en) | 2006-12-04 | 2012-06-05 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating tissue using silk proteins |
| WO2009069986A2 (en) | 2007-11-30 | 2009-06-04 | Korea Research Institute Of Bioscience And Biotechnology | Genetically-modified cell line for producing cloned miniature pigs for xenotransplantation and method for preparing the same. |
| KR101178946B1 (ko) | 2008-02-01 | 2012-09-03 | 한국생명공학연구원 | 알파 1,3-갈락토실트랜스퍼라아제 유전자 타겟팅 벡터 |
| KR101068479B1 (ko) | 2008-07-30 | 2011-09-29 | 한국생명공학연구원 | 알파 1,3-갈락토실트랜스퍼라아제 유전자 타겟팅 벡터 및그의 용도 |
| KR102122267B1 (ko) | 2009-08-14 | 2020-06-12 | 레비비코르 인코포레이션 | 당뇨병 치료를 위한 복수 형질전환 돼지 |
| NZ759163A (en) | 2011-02-14 | 2023-03-31 | Revivicor Inc | Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof |
| WO2013169929A1 (en) | 2012-05-08 | 2013-11-14 | The General Hospital Corporation | Reducing immunogenicity of xenogeneic transplant tissues |
| WO2013188358A1 (en) | 2012-06-12 | 2013-12-19 | The General Hospital Corporation | Miniature swine transgenic for one or more coagulation factors |
| BR112016009178B1 (pt) | 2013-11-04 | 2020-12-15 | Lifecell Corporation | Método de preparação de um produto de tecido e uso de um produto de tecido |
| CN111031790A (zh) | 2017-04-20 | 2020-04-17 | E开创生物技术股份有限公司 | 产生基因修改的动物的方法 |
| JP7431837B2 (ja) | 2018-10-05 | 2024-02-15 | ゼノセラピューティクス インコーポレイテッド | 異種移植製品及び異種移植方法 |
| US10883084B2 (en) | 2018-10-05 | 2021-01-05 | Xenotherapeutics, Inc. | Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same |
| WO2022109316A1 (en) | 2020-11-20 | 2022-05-27 | Revivicor, Inc. | Multi-transgenic pigs with growth hormone receptor knockout for xenotransplantation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994021799A1 (en) * | 1993-03-16 | 1994-09-29 | Austin Research Institute | USE OF PORCINE GAL α(1,3) GALACTOSYL TRANSFERASE IN XENOGRAFT THERAPIES |
| US5849991A (en) * | 1994-01-27 | 1998-12-15 | Bresatch Limited | Mice homozygous for an inactivated α 1,3-galactosyl transferase gene |
-
1995
- 1995-03-31 JP JP7526984A patent/JPH10504442A/ja active Pending
- 1995-03-31 CA CA002187802A patent/CA2187802A1/en not_active Abandoned
- 1995-03-31 DE DE69535752T patent/DE69535752D1/de not_active Expired - Fee Related
- 1995-03-31 WO PCT/US1995/003940 patent/WO1995028412A1/en not_active Ceased
- 1995-03-31 AU AU22332/95A patent/AU2233295A/en not_active Abandoned
- 1995-03-31 EP EP95915459A patent/EP0755402B1/en not_active Revoked
- 1995-03-31 AT AT95915459T patent/ATE395418T1/de not_active IP Right Cessation
- 1995-04-04 IL IL11323895A patent/IL113238A0/xx not_active IP Right Cessation
-
1996
- 1996-03-26 US US08/621,700 patent/US6153428A/en not_active Expired - Lifetime
-
1997
- 1997-09-15 US US08/929,940 patent/US6413769B1/en not_active Expired - Lifetime
-
2002
- 2002-03-15 US US10/098,276 patent/US20030014770A1/en not_active Abandoned
-
2007
- 2007-01-10 JP JP2007026119A patent/JP2007175057A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2187802A1 (en) | 1995-10-26 |
| IL113238A0 (en) | 1995-07-31 |
| US6153428A (en) | 2000-11-28 |
| EP0755402A1 (en) | 1997-01-29 |
| WO1995028412A1 (en) | 1995-10-26 |
| ATE395418T1 (de) | 2008-05-15 |
| EP0755402A4 (en) | 1997-11-26 |
| EP0755402B1 (en) | 2008-05-14 |
| US20030014770A1 (en) | 2003-01-16 |
| AU2233295A (en) | 1995-11-10 |
| JP2007175057A (ja) | 2007-07-12 |
| US6413769B1 (en) | 2002-07-02 |
| DE69535752D1 (de) | 2008-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH10504442A (ja) | α（１，３）ガラクトシルトランスフェラーゼ陰性ブタ | |
| Colledge et al. | Disruption of c-mos causes parthenogenetic development of unfertilized mouse eggs | |
| CA2181433C (en) | Materials and methods for management of hyperacute rejection in human xenotransplantation | |
| EP1071471B1 (en) | Methods and vectors for making transgenic rodents which ubiquitously express a heterologous gene | |
| WO1997007671A1 (en) | Chimeric animal and method for constructing the same | |
| JPH08506014A (ja) | トランスジェニック哺乳動物 | |
| JP2005535343A (ja) | α（１，３）−ガラクトシルトランスフェラーゼ欠損細胞、選択する方法、およびそれらから作製されたα（１，３）−ガラクトシルトランスフェラーゼ欠損ブタ | |
| JPH08504562A (ja) | ウシ種による組み換えポリペプチドの製造及びトランスジェニック法 | |
| JP2003510072A (ja) | 遺伝子発現を改変するための組成物および方法 | |
| US20060057719A1 (en) | Carbohydrate determinant selection system for homologous recombination | |
| JP3741447B2 (ja) | エンドセリン−１遺伝子の機能が欠損したマウス | |
| WO2000039294A1 (en) | Porcine cells incapable of expressing cd40 antigen, for xenotransplantation | |
| Yang et al. | Transgenic farm animals: applications in agriculture and biomedicine | |
| US20060015955A1 (en) | Alpha(1,3)Galactosyltransferase enzyme that assembles the Galalpha(1,3)Gal xenoantigen | |
| KR20100113594A (ko) | 영장류 동물의 초기 배아에의 외래 유전자 도입법 및 상기 도입법을 포함하는 트랜스제닉 영장류 동물을 작출하는 방법 | |
| AU2004200177B2 (en) | Alpha(1,3)-Galactosyltransferase Negative Swine | |
| AU766519B2 (en) | alpha(1,3)-galactosyltransferase negative swine | |
| AU711144B2 (en) | Materials and methods for management of hyperacute rejection in human xenotransplantation | |
| AU752590B2 (en) | H2-O modified transgenic animals | |
| Pinkert | Genetic engineering of farm mammals | |
| AU1850599A (en) | Alpha(1,3)-glactosyltransferase negative swine | |
| WO2001001766A1 (en) | Animal defective in uti gene function | |
| JP2006129736A (ja) | 異種移植用豚細胞、その選抜方法及び異種移植用豚 | |
| JPH09500025A (ja) | 敗血症モデル | |
| WO2001013716A1 (fr) | ANIMAL K-O D'ETUDE DE LA PROTEINE DE TRANSPORT DE L'α-TOCOPHEROL |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060314 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060614 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060912 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070110 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070222 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20070424 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070424 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070614 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20070628 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080624 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090114 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090121 |